NQO1-dependent, tumor-selective radiosensitization of non-small cell lung cancers.

CONCLUSION: Our data suggest that combination of sublethal doses of ß-lap and IR is a viable approach to selectively treat NQO1-overexpressing NSCLC and warrant a clinical trial using low-dose IR + ß-lapachone against patients with NQO1+ NSCLCs.
PMID: 30617135 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 7, 2019 Category: Cancer & Oncology Authors: Motea EA, Huang X, Singh N, Kilgore JA, Williams NS, Xie XJ, Gerber DE, Beg M, Bey EA, Boothman DA Tags: Clin Cancer Res Source Type: research